

Bronchiectasis - Pipeline Review, H1 2020

<https://marketpublishers.com/r/B8FF8EDB649EN.html>

Date: April 2020

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: B8FF8EDB649EN

Abstracts

Bronchiectasis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Pipeline Review, H1 2020, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued

projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 6 and 2 respectively.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).

The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Bronchiectasis - Overview
- Bronchiectasis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Bronchiectasis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bronchiectasis - Companies Involved in Therapeutics Development
- Alitair Pharmaceuticals Inc
- Chiesi Farmaceutici SpA
- Helperby Therapeutics Group Ltd
- Insmmed Inc
- Kamada Ltd
- Novabiotics Ltd
- OrPro Therapeutics Inc
- Parion Sciences Inc
- Polyphor AG
- Recipharm AB
- Santhera Pharmaceuticals Holding AG
- Savara Inc
- Therapeutic Systems Research Laboratories Inc
- Zambon Co SpA
- Bronchiectasis - Drug Profiles
- alpha-1 proteinase inhibitor (human) second generation - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- amikacin sulfate PR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ARD-3150 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
brensocatib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHF-6333 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxofylline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdosteine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
murepavadin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCFBE-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORP-100S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

POL-6014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bronchiectasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tobramycin + triclosan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchiectasis - Dormant Projects

Bronchiectasis - Discontinued Products

Bronchiectasis - Product Development Milestones

Featured News & Press Releases

Feb 03, 2020: Insmmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis

Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference

Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions

May 03, 2017: Insmmed Provides Update On Phase 2 Study Of INS1007

Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA

Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis

Jun 24, 2013: Kamada Receives Two Key Patents Covering Its New Alpha-1 Antitrypsin Product

Jun 09, 2009: Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis

Dec 16, 2008: Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Bronchiectasis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Bronchiectasis - Pipeline by Alitair Pharmaceuticals Inc, H1 2020
Bronchiectasis - Pipeline by Chiesi Farmaceutici SpA, H1 2020
Bronchiectasis - Pipeline by Helperby Therapeutics Group Ltd, H1 2020
Bronchiectasis - Pipeline by Insmmed Inc, H1 2020
Bronchiectasis - Pipeline by Kamada Ltd, H1 2020
Bronchiectasis - Pipeline by Novabiotics Ltd, H1 2020
Bronchiectasis - Pipeline by OrPro Therapeutics Inc, H1 2020
Bronchiectasis - Pipeline by Parion Sciences Inc, H1 2020
Bronchiectasis - Pipeline by Polyphor AG, H1 2020
Bronchiectasis - Pipeline by Recipharm AB, H1 2020
Bronchiectasis - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2020
Bronchiectasis - Pipeline by Savara Inc, H1 2020
Bronchiectasis - Pipeline by Therapeutic Systems Research Laboratories Inc, H1 2020
Bronchiectasis - Pipeline by Zambon Co SpA, H1 2020
Bronchiectasis - Dormant Projects, H1 2020
Bronchiectasis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Bronchiectasis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bronchiectasis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Alitair Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Helperby Therapeutics Group Ltd
Insmmed Inc
Kamada Ltd
Novabiotics Ltd
OrPro Therapeutics Inc
Parion Sciences Inc
Polyphor AG
Recipharm AB
Santhera Pharmaceuticals Holding AG
Savara Inc
Therapeutic Systems Research Laboratories Inc
Zambon Co SpA

I would like to order

Product name: Bronchiectasis - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/B8FF8EDB649EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B8FF8EDB649EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970